1349986-72-6

Basic information

• Product Name: 1,3-dinitrooxy-2-propyl 2-(4-(isobutyl)phenyl)propionate
• CAS NO: 1349986-72-6
• Molecular Weight: 370.359
• Mol File: 1349986-72-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1,3-dinitrooxy-2-propyl 2-(4-(isobutyl)phenyl)propionate(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-dinitrooxy-2-propyl 2-(4-(isobutyl)phenyl)propionate(1349986-72-6)
• EPA Substance Registry System: 1,3-dinitrooxy-2-propyl 2-(4-(isobutyl)phenyl)propionate(1349986-72-6)

Safety Data

• Hazardous Substances Data: 1349986-72-6(Hazardous Substances Data)

Upstream product

• 623-87-0 1,3-bis(nitrooxy)propan-2-ol 
• 71381-91-4 (+/-)-2-(4-isobutylphenyl)propanoyl chloride 

Relevant articles and documents

Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies

A new group of hybrid nitric oxide (NO) releasing anti-inflammatory (AI) ester prodrugs (NONO-NSAIDs) wherein a 1,3-dinitrooxy-2-propyl (12a-c), or O2-acetoxymethyl-1-[2-(methyl)pyrrolidin-1-yl]diazen-1-ium-1, 2-diolate (14a-c), NO-donor moiety is directly attached to the carboxylic acid group of aspirin, indomethacin or ibuprofen were synthesized. NO release from the dinitrooxypropyl, or diazen-1-ium-1,2-diolate, ester prodrugs was increased substantially upon incubation in the presence of l-cysteine (12a-c) or rat serum (14a-c). The ester prodrugs (12a-c, 14a-c), which did not inhibit the COX-1 isozyme, exhibited modest inhibitory activity against the COX-2 isozyme. The NONO-NSAIDs 12a-c and 14a-c exhibited in vivo AI activity that was similar to that exhibited by the parent drug aspirin, indomethacin or ibuprofen when the same oral dose (μmol/kg) was administered. These similarities in oral potency profiles suggest these NONO-NSAIDs act as classical prodrugs that require metabolic activation by esterase-mediated hydrolysis. Hybrid NO-donor/anti-inflammatory prodrugs of this type (NONO-NSAIDs) offer a potential drug design concept targeted toward the development of anti-inflammatory drugs with reduced adverse gastrointestinal effects.